GlaxoSmithKline (GSK), a leading pharmaceutical firm, has embarked on a significant data management overhaul. Recognising the importance of data in modern business, GSK has appointed Mark Ramsey as Chief Data Officer to spearhead this initiative. Ramsey’s primary role is to establish a data management strategy that supports the company’s business objectives.
GSK’s current data management system is fragmented, with different departments using different standards and systems. This lack of consistency hampers the company’s ability to leverage data effectively. Ramsey’s strategy focuses on standardising data management across the firm, ensuring data quality, and promoting data literacy among employees.
A key aspect of this strategy is the use of machine learning and artificial intelligence to manage and analyse data. GSK has partnered with Palantir Technologies, a software company specialising in big data analytics, to develop a data management platform. This platform will integrate data from various sources, enabling GSK to gain insights that can drive business decisions and improve patient outcomes.
Despite the challenges, Ramsey is optimistic about the data management overhaul. He believes that with the right approach and tools, GSK can transform its data into a valuable asset that supports its mission of improving people’s health.
Go to source article: https://www.forbes.com/sites/tomdavenport/2018/01/08/biting-the-data-management-bullet-at-glaxosmithkline/#656843245577